Diethyl 1,4-dioxaspiro[4.5]decane-2,3-dicarboxylate | 93922-63-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Diethyl 1,4-dioxaspiro[4.5]decane-2,3-dicarboxylate
• CAS: 93922-63-5
• 化学式: C₁₄H₂₂O₆
• 分子量: 286.32
• InChiKey: PGTQQJKIKPXQAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Diethyl 1,4-dioxaspiro[4.5]decane-2,3-dicarboxylate 、 ammonium hydroxide 以10%的产率得到
  参考文献：
  名称：

  WOLINSKI, J.;GOLUBIC, H., ACTA POL. PHARM., 1983, 40, N 5-6, 551-554

  摘要：

  DOI：
• 作为产物：
  描述：

  环己酮 、 L-酒石酸 、 乙醇 、 甲苯 、 盐酸 以21%的产率得到
  参考文献：
  名称：

  WOLINSKI, J.;GOLUBIC, H., ACTA POL. PHARM., 1983, 40, N 5-6, 551-554

  摘要：

  DOI：

文献信息

• Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：Aicher Thomas Daniel

  公开号：US20100204240A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及本文所讨论的其他疾病和紊乱。
• Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：AICHER Thomas Daniel

  公开号：US20120277242A1

  公开（公告）日：2012-11-01

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  本发明提供了式(I)的化合物：其中R2、R3、R13、L和D2如规范中所定义，它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用，或者可以通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及其他疾病和疾病，如在此处所讨论的。
• INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES
  申请人：Array BioPharma Inc.

  公开号：US20150057448A1

  公开（公告）日：2015-02-26

  Provided are intermediates having the formulas wherein R 2 , R 3 , and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.

  提供了中间体的公式，其中R2，R3和L的定义如规范中所述，这些中间体在制备吡啶-2-基氨基-1,2,4-噻二唑衍生物中很有用。
• Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
  申请人：Array Biopharma, Inc.

  公开号：EP2573087A1

  公开（公告）日：2013-03-27

  Provided are compounds of Formula I wherein R2, R3, R13 , L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供了式 I 的化合物 其中 R2、R3、R13、L 和 D2 如说明书中所定义，可用于治疗和/或预防由葡萄糖激酶活性水平不足介导或可通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、空腹血糖受损和空腹血糖升高，以及其它疾病和紊乱，如本文所讨论的疾病和紊乱。
• PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS
  申请人：Array Biopharma, Inc.

  公开号：EP3078662A1

  公开（公告）日：2016-10-12

  Provided are compounds of Formula I wherein R2, R3, R13 , L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供了式 I 的化合物 其中 R2、R3、R13、L 和 D2 如说明书中所定义，可用于治疗和/或预防由葡萄糖激酶活性水平不足介导或可通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、空腹血糖受损和空腹血糖升高，以及其它疾病和紊乱，如本文所讨论的疾病和紊乱。